CMPX - Company ID 0001738021
The table below shows Compass Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $0.00 | $0.00 | - | $0.00 | $850.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $13.39M | $12.83M | $16.41M | $13.05M | $8.61M | $11.17M |
Compass Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $850.00K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $6.91M |
| $2.99M |
| $4.65M |
| $4.91M |
| $3.63M |
| $4.72M |
| Operating income | -$20.30M | -$15.82M | -$21.07M | -$17.97M | -$12.24M | -$15.04M |
| Income tax | - | - | - | $0.00 | - | $0.00 |
| Net income | -$18.32M | -$14.26M | -$19.88M | -$16.63M | -$10.48M | -$13.08M |
| EPS (diluted) | - | - | - | - | - | - |